Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To compare the efficacy and safety of alogliptin, a dipeptidyl peptidase‐4 (DPP‐4) enzyme inhibitor, in elderly (≥65) and younger (<65) patients with type 2 diabetes mellitus. DESIGN: Pooled analysis of six randomized, double‐blind, placebo‐controlled studies of alogliptin. PARTICIPANTS: Patients aged 18 to 80 with type 2 diabetes mellitus and inadequate glycemic control. INTERVENTIONS: Elderly (mean age 70.0; n=455) and younger (mean age 51.8; n=1,911) patients received alogliptin 12.5 mg (n=922), alogliptin 25 mg (n=910), or placebo (n=534) for 26 weeks (12 weeks in a Phase 2 study). The studies evaluated alogliptin as monotherapy and coadministered with pioglitazone, glyburide, metformin, or insulin. MEASUREMENTS: Efficacy endpoints included change from baseline in glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), weight, and lipid values. Safety variables included hypoglycemic events, adverse events, and blood pressure. RESULTS: Least‐squares mean HbA1c decreased from baseline by 0.7% and 0.8% in elderly patients receiving alogliptin 12.5 and 25 mg, respectively, and 0.5% and 0.6%, respectively, in younger patients ( P <.001 for both alogliptin doses vs placebo for both age groups P =.70 for 12.5 mg and .68 for 25 mg for differences between age groups). Results were similar for FPG. Incidence of hypoglycemia was 8.3% or less in all alogliptin groups (≤10.5% for placebo), with no apparent difference between elderly and younger patients. Changes in weight were negligible in all treatment groups in both age categories. The safety profiles of alogliptin were similar in the age and dose groups. CONCLUSION: Alogliptin was effective and well tolerated in the elderly patients enrolled in these studies. Improvements in HbA1c were similar to those seen in younger patients, and no increase in the risk of hypoglycemia, weight gain, or other adverse events was apparent in elderly patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Meier, J. J., Nauck, M. A., Kranz, D., Holst, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E., & Gallwitz, B. (2004) · Diabetes · doi:10.2337/diabetes.53.3.654 · Cited by 334 · cited 1×
“The DPP-4 enzyme rapidly inactivates glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), incretin hormones released postprandially from gut endocrine cells that stimulate insulin secretion and inhibit postprandial glucagon secretion in a glucose-dependent manner.(15,16) An impaired…”
BackgroundThe burden and treatment of diabetes in elderly individuals in the U.S
Selvin, E., Coresh, J., & Brancati, F. L. (2006) · Diabetes Care · doi:10.2337/dc06-1058 · Cited by 261
Individual Sulfonylureas and Serious Hypoglycemia in Older People
Shorr, R. I., Ray, W. A., Daugherty, J. R., & Griffin, M. R. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb03729.x · Cited by 221
Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes
Meneilly, G. S., Cheung, E., & Tuokko, H. (1994) · Diabetes · doi:10.2337/diab.43.3.403 · Cited by 167
Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes
Meneilly, G. S., Cheung, E., & Tuokko, H. (1994) · Diabetes · doi:10.2337/diabetes.43.3.403 · Cited by 167
Cited by
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Deacon, C. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00080 · Cited by 428
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Deacon, C. F. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0399-8 · Cited by 398
Diabetes in older people: new insights and remaining challenges
Sinclair, A., Dunning, T., & Rodriguez-Mañas, L. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70176-7 · Cited by 302
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial
Leiter, L. A., Teoh, H., Braunwald, E., Mosenzon, O., Cahn, A., Kumar, K. M. P., Smahelova, A., Hirshberg, B., Stahre, C., Frederich, R., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2868 · Cited by 87
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
Giugliano, D., Sportiello, L., Capuano, A., Maiorino, M., Rossi, F., & Esposito, K. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s37647 · Cited by 86
Metadata
- Authors
- Pratley, R. E., McCall, T., Fleck, P. R., Wilson, C. A., & Mekki, Q.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2009-10-27
- Volume
- 57
- Issue
- 11
- Pages
- 2011-2019
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W1569365382
- Cited by
- 78
- References
- 7
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies. https://app.cochat.ai/papers/10.1111/j.1532-5415.2009.02484.x
- The paper
- Pratley, R. E., McCall, T., Fleck, P. R., Wilson, C. A., & Mekki, Q. (2009). Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2009.02484.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.